Skip to main content

Our Impact

Our Impact

The results of our research are changing the way patients are treated around the world.

We aim for our ground-breaking research to deliver changes to clinical care. Take a look at our case studies which illustrate how we are achieving our goal.

 

  • A new technique to prevent transmission of mitochondrial disease
  • Approval of eculizumab and establishment of a national service to treat patients with Atypical Haemolytic Uraemic Syndrome 
  • Endocuff Vision: a simple tool to increase early detection of cancerous lesions in the colon 
  • The use of diet to reverse type 2 diabetes 
  • Ataluren: the first approved oral treatment for Duchenne muscular dystrophy 
  • Rucaparib for the treatment of germline and somatic HRD cancers 
  • Aspirin to decrease the risk of colorectal cancer for patients with Lynch syndrome 

 

synovial-tissue

  • Treatment stratification for medulloblastoma patients 
  • Human-derived limbal cell transplant to treat chemical burns of the eye 
  • Approval of the first licensed medication to treat drooling in children with neurodisability 
  • Optimising thrombectomy services to improve patient outcomes from stroke 
  • Non-coercive, forensic interview training 
  • Erdafitinib, the first-in-class treatment of bladder cancer 
  • Skimune, a test for adverse immune reactions to compounds including chemical cosmetics and novel pharmaceuticals
people-in-laboratory